The global

Bortezomib Market

is valued at

USD 25.1 Million in 2024

and is projected to reach a value of

USD 41.16 Million by 2035

at a CAGR (Compound Annual Growth Rate) of

4.6%

between 2025 and 2035.

Bortezomib is a cancer treatment drug primarily used for blood cancers like multiple myeloma and mantle cell lymphoma. It belongs to the proteasome inhibitor class, which works by blocking proteasomes cellular structures responsible for protein breakdown.

Key Highlights

• Based on the Types, the 1mg category accounted for significant market share in Bortezomib market industry in 2024
• In 2024, by Applications, Multiple Myeloma dominated the Bortezomib market with significant market share of 55.5%
• In 2024, based on Dosage, Community Injection dominated the market with significant market share
• In 2024, by End-Users, Hospital dominated the market with market share of 51.5%
• North America dominated the Bortezomib market industry with 46.5% Bortezomib market share in 2024
• Asia Pacific region is anticipated to grow at the highest CAGR of 18.9% during the forecast period in Bortezomib market industry

{{bar_graph}}

Types Overview

​The Types segment is divided into 1mg, 3.5mg, 5mg, Others. The 1mg segment held the significant Bortezomib market size in 2024.

The 1mg led the Bortezomib market industry in 2024, capturing over significant revenue. 1mg dosage is commonly prescribed due to its effectiveness in treating multiple myeloma and mantle cell lymphoma, offering a balanced approach for patients undergoing chemotherapy. The 1mg formulation is preferred for its ease of administration and is widely used in both frontline and relapsed treatment regimens. Its strong market position is driven by its established clinical efficacy and its integration into standard treatment protocols across various healthcare settings.

Applications Overview

​The Applications segment is divided into Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Others. The Multiple Myeloma segment held the dominant share in 2024, accounting for significant Bortezomib industry share of 55.5%.

Multiple Myeloma held the largest market share in the global Bortezomib industry in 2024 driven by its position as the second most common hematologic cancer after non-Hodgkins lymphoma. Originating from plasma cells in the bone marrow, multiple myeloma leads to complications such as anemia, kidney dysfunction, and bone fractures. It represents approximately 1% of all cancers, with over 30,000 new cases diagnosed annually in the U.S.

Bortezomib has transformed the treatment landscape for multiple myeloma by introducing a novel mechanism of action targeting the proteasome pathway. This breakthrough formed the foundation for new clinical regimens, with trials consistently demonstrating its ability to improve response rates, progression-free survival, and overall survival compared to earlier therapies. As a result, bortezomib is now a cornerstone of both frontline and relapse treatment strategies, firmly embedded in major clinical guidelines.

End-Users Overview

​The End-Users segment is divided into Clinic, Hospital, Others. Hospital segment held the dominant share in 2024, accounting for significant Bortezomib industry share of 51.5%.

The Hospital segment led the global Bortezomib industry in 2024 and expected to grow at the fastest rate due to its suitability for administering chemotherapy treatments. While outpatient oncology clinics also use bortezomib, hospitals provide significant advantages. Most multiple myeloma patients undergo cycles of bortezomib alongside other intravenously delivered drugs, making hospitals ideal with their dedicated chemotherapy suites, skilled oncology staff, and inpatient facilities to manage side effects or complications.

For conditions like relapsed or refractory multiple myeloma, which often require multiple lines of treatment, hospitals ensure seamless care coordination through specialized teams that monitor patients throughout extended treatment durations. Their larger scale allows access to treatment for a broader patient demographic across various locations. Many physicians prefer administering bortezomib in hospitals due to the comprehensive support systems available. Additionally, reimbursement policies in many countries favor hospital-based chemotherapy, further solidifying their role as the primary end-use sector driving bortezomib utilization globally.

Regional Overview

In 2024, the Bortezomib market size of the North America is USD 11.67 Million.

North America

Bortezomib industry report is driven by a well-established healthcare system, a high prevalence of multiple myeloma, and supportive reimbursement policies. Significant R&D investments by key industry players foster innovation and market expansion. The regions strong patient awareness and ongoing clinical trials further boost the adoption of bortezomib as a cancer treatment.

Europe Bortezomib Market Analysis

In 2024, the Europes led the Bortezomib Market, driven by rising cancer rates, government initiatives to improve cancer care, and advanced medical technologies. The aging population in the region increases the demand for cancer therapies, including bortezomib. Accessible healthcare systems and heightened awareness about cancer contribute to market growth, alongside substantial investments in oncology research.

Asia Pacific

Bortezomib Market Analysis

The Asia Pacific Bortezomib market is expected to grow at a robust CAGR of 18.9% during the forecast period. Asia Pacific’s growth is fueled by improved healthcare infrastructure, rising disposable incomes, and greater awareness of cancer diagnosis and treatment options. The increasing prevalence of multiple myeloma and lymphoma in the region drives demand for advanced cancer therapies like bortezomib. Additionally, investments in the healthcare sector and the expanding pharmaceutical industry further accelerate Bortezomib market development.

Based on the provided market data, Vantage Market Research offers customizations in the reports to meet the specific needs of clients.

Bortezomib Market Trends

• 
  

  Combination Therapies:

  
  

  Increasing use of bortezomib in combination with immunomodulators and monoclonal antibodies for improved efficacy in multiple myeloma treatment

• 
  

  Subcutaneous Formulations:

  
  

  Growing preference for subcutaneous over intravenous formulations due to better patient convenience and fewer side effects

• 
  

  Generic Competition:

  
  

  Patent expiration of Velcade has led to increased availability of cost-effective generic versions, expanding patient access but reducing branded revenues

• 
  

  Novel Delivery Systems:

  
  

  Development of advanced formulations to enhance efficacy and differentiate from generics

• 
  

  Rising Disease Prevalence:

  
  

  Increasing multiple myeloma cases, especially in aging populations, driving demand for effective treatments like bortezomib

• 
  

  Personalized Medicine

  
  

  
  

  :

  
  

  Integration into tailored treatment plans based on genetic profiling for optimized outcomes

{{dialog}}

{{dashboard_image}}

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool:

Vantage Point

Market Dynamics

Market Drivers for Bortezomib Market

Rising Prevalence of Multiple Myeloma

Cancer affects plasma cells responsible for immune defense, predominantly impacts older adults, with age, genetics, and family history being significant risk factors. The disease is rare in individuals under 40 but becomes increasingly common with age. As global life expectancy rises, the aging population expands, leading to a larger pool of individuals susceptible to multiple myeloma. This growing prevalence drives demand for effective treatment options like bortezomib, a widely prescribed drug for the disease. Multiple myeloma, if untreated, can result in severe complications such as bone lesions, marrow suppression, and fatality. The increased disease burden, particularly in aging populations with improved healthcare access, has significantly boosted the demand for bortezomib in regions like North America and Europe over the past decade.

Market Restraints for Bortezomib market

Impact of Patent Expiry hinders Bortezomib market growth

The expiration of Velcades patent in 2020 has posed challenges for the Bortezomib market. With the introduction of generic alternatives, treatment costs have decreased, impacting the revenues of established manufacturers. This price competition threatens market share for companies that relied on Velcade’s exclusivity. To counteract this, manufacturers are focusing on expanding bortezomib’s approved indications and introducing innovative delivery methods to differentiate their products and sustain Bortezomib market presence.

Market Opportunities for Bortezomib market

Emerging markets in Asia Pacific and Latin America present significant growth opportunities for the Bortezomib market

Asia Pacific and Latin America are experiencing a rise in blood cancer cases, including multiple myeloma, due to aging populations and lifestyle changes. Historically, low treatment rates in these areas were attributed to economic constraints and limited access to advanced therapies. However, increasing healthcare investments, improved medical awareness, and broader health insurance coverage are enabling greater access to novel treatments like bortezomib. These Bortezomib markets also offer advantages such as less stringent regulatory environments and fewer price controls compared to developed regions. Leading players can capitalize on these opportunities by forming manufacturing and distribution partnerships with local companies to strengthen their presence in these high-growth Bortezomib markets.

Competitive Landscape

The Bortezomib market industry report is shaped by the presence of key pharmaceutical players, ongoing innovations, and a growing focus on combination therapies for multiple myeloma and other hematologic malignancies. Leading companies such as Takeda Pharmaceuticals, the original developer of Velcade (bortezomib), face competition from generic manufacturers offering cost-effective alternatives following patent expirations. The market is further influenced by advancements in drug delivery systems, such as subcutaneous formulations, and the integration of bortezomib in combination regimens with newer agents like monoclonal antibodies and immunomodulatory drugs. Clinical trials exploring novel combinations and expanded indications continue to drive differentiation among competitors, while partnerships and licensing agreements enhance market penetration and accessibility across various regions.

The key players in the global Bortezomib market report include - Sonoco Products Company, Cryopak Europe, Pelican BioThermal, Cold & Co, ACH Foam Technologies Inc., Saeplast, AccsA’tech, Insulated Products Corporation, TKT GmbH, Snyder Industries, Envirotainer AB among others.

Recent Market Developments

FDA Approves Darzalex Faspro Combination Therapy for Newly Diagnosed Multiple Myeloma Patients Eligible for ASCT

• In July 30, 2024, the U.S. FDA approved the combination of daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Research & Development, LLC) with bortezomib, lenalidomide, and dexamethasone for use in induction and consolidation therapy for newly diagnosed multiple myeloma patients eligible for autologous stem cell transplant (ASCT)

GSK’s DREAMM-7 Trial Shows Belantamab Mafodotin Outperforms Daratumumab in Relapsed or Refractory Multiple Myeloma

• In November 2024, GSK plc reported positive interim results from the DREAMM-7 Phase III trial. The study demonstrated that belantamab mafodotin, when combined with bortezomib and dexamethasone (BorDex), significantly improved progression-free survival (PFS) compared to daratumumab plus BorDex in patients with relapsed or refractory multiple myeloma. Additionally, the trial showed a strong trend toward enhanced overall survival (OS), with a nominal p-value of < 0.0005, and OS follow-up is still ongoing

The global Bortezomib market can be categorized as Types, Applications, Route of Administration, Dosage, Distribution Channel, End-Users and Region.